On September 27, CMS issued a final decision approving beta-amyloid PET under the agency's coverage with evidence development (CED) protocol for patients enrolled in an approved clinical study.
Although MITA appreciates that CMS is offering beta-amyloid PET to some Medicare beneficiaries, the group is disappointed there will not be coverage for beta-amyloid PET without CED for patients with suspected dementia or Alzheimer's disease who meet specific appropriate-use criteria.
The organization will continue to work with CMS toward a substantive, feasible CED program that will support broader access for Medicare patients, according to Gail Rodriguez, executive director of MITA. If you like this content, please share it with a colleague!
Copyright © 2013 AuntMinnie.com